Leukemia-Lymphoma 2023 | CURE

New Horizons for Diffuse Large B-Cell Lymphoma

September 13, 2023

Article

Recent advancements in treatment options for patients with diffuse large B-cell lymphoma have been practice-changing.

‘Pivotal’ Time for DLBCL Treatment Options

September 07, 2023

Article

The Food and Drug Administration, in a flurry of activity, approved three new medications across a three-month period earlier this year.

Minimal Residual Disease Remains An Evolving and Game-Changing Field

September 06, 2023

Article

MRD testing began among patients with chronic myeloid leukemia, a disease that lends itself to gauging MRD because it is driven by a specific genetic mutation.

On the Lookout for Minimal Residual Disease in Leukemia

September 06, 2023

Article

Why minimal residual disease testing is the "gold standard" for some patients and providers.